Oncology study for GBM and other CNS tumours (S17ACC06)

This research study is testing a new drug called ACT001, which is an investigational drug that has been shown to slow or stop the growth of cancer cells. In addition, the study will look at the amount of drug in the blood to evaluate the way the body processes the drug and the way the drug behaves to the growth of tumours in cancer patients. A major purpose of this study is to find out a safe dose range of ACT001 that can be given to humans.

Studies in animals indicate that ACT001 can slow or stop the growth of some of the tumour types tested. These include glioblastoma (a malignant brain tumour) and some types of leukaemia. It is thought that ACT001 suppresses the activity of a group of cancer-causing proteins known as the NF-kB pathway. It appears to achieve this by turning off the function of an important protein in this pathway called IKKβ. It is possible that these effects on IKKβ and the NF-kB pathway are an important part of how ACT001 works against cancer cells.

This research study will help us understand whether ACT001, the investigational product, can be safely given to patients experiencing cancer.

ACT001 is a tablet that is taken twice per day continuously for as long as there is clinical benefit.

This clinical study is currently recruiting participants.

If you would like more information, register below or call 1800 727 874.

No inpatient stay required

Weekly visits for first 4 weeks, fortnightly for next 4 weeks, then monthly thereafter

*have a CNS tumour such as GBM that has progressed after radiation and adjuvant TMZ

When enquiring about this clinical study please quote the study code above